Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results
May 08 2018 - 6:30AM
Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in molecular
diagnostics and personalized medicine, today announced financial
results for its fiscal third-quarter 2018, provided an update on
recent business highlights and raised its fiscal year 2018
financial guidance.
"We saw strong results in the third quarter with financial
performance once again exceeding our expectations due to better
than anticipated hereditary cancer volumes, strong new product
volume growth and the success of our Elevate 2020 program,” said
Mark C. Capone, president and CEO, Myriad Genetics. “Our
diversification efforts achieved record results in the third
quarter, with new products now representing 71 percent of sample
volume and 36 percent of revenue. And the landmark GeneSight®
clinical trial results have led to our first commercial coverage
decision. Given that this new product growth is being built upon a
solid hereditary cancer foundation, we are raising our financial
guidance for fiscal year 2018.”
Financial HighlightsThe following table
summarizes the financial results for the fiscal third-quarter
2018:
Revenue |
|
|
|
|
|
|
|
|
|
|
Fiscal Third-Quarter |
|
|
($
in millions) |
|
2018 |
|
|
2017 |
|
% Change |
Molecular
diagnostic testing revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hereditary cancer
testing revenue |
$ |
123.3 |
|
|
$ |
140.8 |
|
|
(12 |
%) |
|
|
|
|
|
|
|
|
|
|
GeneSight testing
revenue |
|
30.4 |
|
|
|
23.9 |
|
|
27 |
% |
|
|
|
|
|
|
|
|
|
|
Vectra DA testing
revenue |
|
15.0 |
|
|
|
11.2 |
|
|
34 |
% |
|
|
|
|
|
|
|
|
|
|
Prolaris testing
revenue |
|
6.5 |
|
|
|
3.4 |
|
|
91 |
% |
|
|
|
|
|
|
|
|
|
|
EndoPredict testing
revenue |
|
2.3 |
|
|
|
2.3 |
|
|
0 |
% |
|
|
|
|
|
|
|
|
|
|
Other testing
revenue |
|
2.2 |
|
|
|
3.6 |
|
|
(39 |
%) |
|
|
|
|
|
|
|
|
|
Total
molecular diagnostic testing revenue |
|
179.7 |
|
|
|
185.2 |
|
|
(3 |
%) |
|
|
|
|
|
|
|
|
|
Pharmaceutical and clinical service revenue |
|
13.8 |
|
|
|
11.7 |
|
|
18 |
% |
|
|
|
|
|
|
|
|
|
Total
Revenue |
$ |
193.5 |
|
|
$ |
196.9 |
|
|
(2 |
%) |
|
|
|
|
|
|
|
|
|
Income Statement |
|
|
|
|
|
|
|
|
|
|
Fiscal Third-Quarter |
|
|
($
in millions) |
|
2018 |
|
|
2017 |
|
% Change |
Total
Revenue |
$ |
193.5 |
|
|
$ |
196.9 |
|
|
(2 |
%) |
|
|
|
|
|
|
|
|
|
Gross
Profit |
|
149.4 |
|
|
|
152.6 |
|
|
(2 |
%) |
|
Gross Margin |
|
77.2 |
% |
|
|
77.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
Operating
Expenses |
|
132.4 |
|
|
|
144.9 |
|
|
(9 |
%) |
|
|
|
|
|
|
|
|
|
Operating
Income |
|
17.0 |
|
|
|
7.7 |
|
|
121 |
% |
|
Operating Margin |
|
8.8 |
% |
|
|
3.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
Adjusted
Operating Income |
|
28.6 |
|
|
|
24.0 |
|
|
19 |
% |
|
Adjusted Operating
Margin |
|
14.8 |
% |
|
|
12.2 |
% |
|
|
|
|
|
|
|
|
|
|
|
Net
Income |
|
11.4 |
|
|
|
4.2 |
|
|
171 |
% |
|
|
|
|
|
|
|
|
|
Diluted
EPS |
|
0.16 |
|
|
|
0.06 |
|
|
167 |
% |
|
|
|
|
|
|
|
|
|
Adjusted
EPS |
$ |
0.31 |
|
|
$ |
0.27 |
|
|
15 |
% |
|
|
|
|
|
|
|
|
|
|
|
Business Highlights
• Hereditary Cancer
- Achieved the fifth consecutive quarter of year-over-year
hereditary cancer volume growth with total hereditary cancer volume
exceeding our three percent growth target on a year-over-year
basis.
- riskScore® led to accelerating growth in our
preventive care segment over the last two quarters.
• GeneSight®
- Revenue increased 27 percent year-over-year to $30.4 million
with record volumes in the quarter.
- Myriad has been notified of a commercial coverage decision from
a top-20, mid-Atlantic payer.
- Presented data from the largest-ever pharmacogenomics clinical
study in patients with moderate-to-very severe depression at the
American Psychiatric Association annual meeting in New York City,
demonstrating that patients were 50 percent more likely to achieve
remission and 30 percent more likely to respond to treatment when
their medication selection was guided by the GeneSight Psychotropic
genetic test.
- Submitted the randomized controlled trial study manuscript to a
peer-reviewed journal and anticipate publication around the end of
fiscal year 2018.
- Submitted manuscripts for the IMPACT study and a second major
health economic study utilizing the Optum Healthcare Solutions
dataset.
• Vectra DA®
- Revenue increased 34 percent year-over-year in the quarter with
volumes growing in the double-digits on a sequential basis.
- Initiated plans to move the Vectra DA customer service group
and commercial laboratory to our Salt Lake City headquarters with
plans to complete both moves by the end of fiscal year 2019.
• Prolaris®
- Revenue in the quarter increased 91 percent year-over-year to
$6.5 million and test volumes grew 10 percent sequentially.
- NCCN issued new guidelines supporting Prolaris as standard
of care for treatment decisions in patients with low
and favorable-intermediate risk prostate cancer. The
guidelines also support the broad use of hereditary cancer testing
in 40,000 specific prostate cancer patients diagnosed every year in
the United States and support the use of biomarkers such as
myChoice® HRD Plus to identify prostate cancer patients for
targeted therapies.
- American Association of Clinical Urology and the Large Urology
Group Practice Association, that represent 70 percent of urologists
in the country, issued a position paper supporting the new NCCN
guidelines.
- Received positive medical policy recommendations for Prolaris
in the quarter from 14 Medicaid states, first Blue Cross Blue
Shield plan and several regional payers.
• EndoPredict®
- Reported $2.3 million in the quarter an increase of 15 percent
sequentially.
- Received final Medicare local coverage decision from Noridian
which became effective on January 30 increasing total coverage to
approximately 90 percent of the United States market.
- One of the largest private insurers in the United States has
expanded its coverage policy on EndoPredict to aid in the clinical
decision of whether or not to extend adjuvant hormonal therapy
beyond five years of treatment.
• Companion Diagnostics
- Received Food and Drug Administration approval for
BRACAnalysis® CDx as a companion diagnostic in
conjunction with AstraZeneca’s Lynparza (olaparib) for HER2-
metastatic breast cancer.
- Launched BRACAnalysis CDx to approximately 3,000 oncologists
who treat greater than two-thirds of metastatic breast cancer and
saw a 70 percent increase in metastatic breast cancer testing in
the third quarter compared to the second quarter.
• International
- Received a revised draft guidance document from the United
Kingdom’s National Institute for Health and Care Excellence (NICE)
which includes EndoPredict as one of three approved breast cancer
prognostic tests.
- Initiated a restructuring to shift all laboratory developed
testing to United States laboratories which will lead to closing
the laboratory in Munich Germany and the sale of the German
Clinic.
- Received pre-market approval from the Japanese Ministry of
Health, Labor, and Welfare for our BRACAnalysis CDx test for HER2-
metastatic breast cancer.
Fiscal Year 2018 Financial GuidanceBelow is a
table summarizing Myriad’s fiscal year 2018 financial guidance:
|
|
|
|
|
|
|
Revenue |
|
GAAP DilutedEarnings PerShare |
|
Adjusted EarningsPer Share |
Fiscal Year 2018 |
$771-$773 million |
|
$1.87-$1.89 |
|
$1.19-$1.21 |
|
|
|
|
|
|
These projections are forward-looking statements and are subject
to the risks summarized in the safe harbor statement at the end of
this press release. The Company will provide further details
on its business outlook during the conference call today and
discuss the fiscal third-quarter financial results, and fiscal year
2018 financial guidance.
Conference Call and WebcastA conference call
will be held today, Tuesday, May 8, 2018, at 7:30 a.m. EDT to
discuss Myriad’s financial results for the fiscal third-quarter,
business developments and financial guidance. The dial-in
number for domestic callers is 1-800-699-0623. International
callers may dial 1-303-223-4362. All callers will be asked to
reference reservation number 21887258. An archived replay of
the call will be available for seven days by dialing (800) 633-8284
and entering the reservation number above. The conference
call along with a slide presentation will also will be available
through a live webcast at www.myriad.com.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five strategic imperatives: building upon a solid hereditary
cancer foundation, growing new product volume, expanding
reimbursement coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G.
|
|
|
|
|
|
|
|
|
MYRIAD GENETICS, INC. AND SUBSIDIARIES |
|
|
|
|
|
|
|
|
CONSOLIDATED INCOME STATEMENTS
(Unaudited) |
|
|
|
|
|
|
|
(in millions, except
per share amounts) |
|
|
|
|
|
|
|
|
|
|
Three months ended |
|
Nine months ended |
|
|
March 31, |
|
March 31, |
|
|
2018 |
|
2017 |
|
2018 |
|
2017 |
Molecular diagnostic
testing |
|
$ |
179.7 |
|
|
$ |
185.2 |
|
|
$ |
537.6 |
|
|
$ |
534.2 |
|
Pharmaceutical and
clinical services |
|
|
13.8 |
|
|
|
11.7 |
|
|
|
40.1 |
|
|
|
36.7 |
|
Total
revenue |
|
|
193.5 |
|
|
|
196.9 |
|
|
|
577.7 |
|
|
|
570.9 |
|
Costs and
expenses: |
|
|
|
|
|
|
|
|
Cost of
molecular diagnostic testing |
|
|
36.8 |
|
|
|
37.9 |
|
|
|
110.7 |
|
|
|
109.5 |
|
Cost of
pharmaceutical and clinical services |
|
|
7.3 |
|
|
|
6.4 |
|
|
|
20.7 |
|
|
|
19.1 |
|
Research
and development expense |
|
|
18.5 |
|
|
|
17.6 |
|
|
|
53.1 |
|
|
|
55.6 |
|
Change in
the fair value of contingent consideration |
|
|
(1.2 |
) |
|
|
5.2 |
|
|
|
(61.3 |
) |
|
|
2.0 |
|
Selling,
general, and administrative expense |
|
|
115.1 |
|
|
|
122.1 |
|
|
|
345.5 |
|
|
|
354.3 |
|
Total
costs and expenses |
|
|
176.5 |
|
|
|
189.2 |
|
|
|
468.7 |
|
|
|
540.5 |
|
Operating
income |
|
|
17.0 |
|
|
|
7.7 |
|
|
|
109.0 |
|
|
|
30.4 |
|
Other income
(expense): |
|
|
|
|
|
|
|
|
Interest
income |
|
|
0.5 |
|
|
|
0.3 |
|
|
|
1.2 |
|
|
|
0.9 |
|
Interest
expense |
|
|
(0.5 |
) |
|
|
(1.5 |
) |
|
|
(2.2 |
) |
|
|
(4.8 |
) |
Other |
|
|
(0.5 |
) |
|
|
1.5 |
|
|
|
(1.3 |
) |
|
|
(2.4 |
) |
Total
other income (expense): |
|
|
(0.5 |
) |
|
|
0.3 |
|
|
|
(2.3 |
) |
|
|
(6.3 |
) |
Income
before income tax |
|
|
16.5 |
|
|
|
8.0 |
|
|
|
106.7 |
|
|
|
24.1 |
|
Income tax
provision |
|
|
5.2 |
|
|
|
3.8 |
|
|
|
(17.7 |
) |
|
|
15.2 |
|
Net income |
|
$ |
11.3 |
|
|
$ |
4.2 |
|
|
$ |
124.4 |
|
|
$ |
8.9 |
|
Net loss attributable
to non-controlling interest |
|
|
(0.1 |
) |
|
|
— |
|
|
|
(0.2 |
) |
|
|
(0.1 |
) |
Net income attributable
to Myriad Genetics, Inc. stockholders |
|
$ |
11.4 |
|
|
$ |
4.2 |
|
|
$ |
124.6 |
|
|
$ |
9.0 |
|
Earnings per
share: |
|
|
|
|
|
|
|
|
Basic |
|
$ |
0.16 |
|
|
$ |
0.06 |
|
|
$ |
1.80 |
|
|
$ |
0.13 |
|
Diluted |
|
$ |
0.16 |
|
|
$ |
0.06 |
|
|
$ |
1.74 |
|
|
$ |
0.13 |
|
Weighted average shares
outstanding: |
|
|
|
|
|
|
|
|
Basic |
|
|
69.8 |
|
|
|
68.1 |
|
|
|
69.2 |
|
|
|
68.1 |
|
Diluted |
|
|
72.4 |
|
|
|
68.3 |
|
|
|
71.7 |
|
|
|
68.5 |
|
|
|
|
|
|
|
|
|
|
|
Consolidated Balance Sheets (Unaudited) |
(in millions) |
|
|
|
|
|
|
March 31, |
|
June 30, |
ASSETS |
|
2018 |
|
2017 |
Current
assets: |
|
|
|
|
Cash and
cash equivalents |
|
$ |
97.4 |
|
$ |
102.4 |
|
Marketable investment securities |
|
|
59.9 |
|
|
48.3 |
|
Prepaid
expenses |
|
|
10.1 |
|
|
12.7 |
|
Inventory |
|
|
33.4 |
|
|
42.2 |
|
Trade
accounts receivable, less allowance for doubtful accounts of $10.3
March 31, 2018 and $8.2 June 30, 2017 |
|
|
123.7 |
|
|
105.6 |
|
Prepaid
taxes |
|
|
3.7 |
|
|
0.2 |
|
Other
receivables |
|
|
3.3 |
|
|
5.7 |
|
Total
current assets |
|
|
331.5 |
|
|
317.1 |
|
Property, plant and equipment, net |
|
|
48.2 |
|
|
51.1 |
|
Long-term marketable investment securities |
|
|
51.3 |
|
|
48.5 |
|
Intangibles, net |
|
|
467.3 |
|
|
491.6 |
|
Goodwill |
|
|
320.2 |
|
|
316.1 |
|
Total
assets |
|
$ |
1,218.5 |
|
$ |
1,224.4 |
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
Current
liabilities: |
|
|
|
|
Accounts
payable |
|
$ |
20.2 |
|
$ |
22.0 |
|
Accrued
liabilities |
|
|
64.1 |
|
|
65.6 |
|
Short-term contingent consideration |
|
|
7.4 |
|
|
127.3 |
|
Deferred
revenue |
|
|
2.6 |
|
|
2.6 |
|
Total
current liabilities |
|
|
94.3 |
|
|
217.5 |
|
Unrecognized tax benefits |
|
|
27.9 |
|
|
25.2 |
|
Other
long-term liabilities |
|
|
6.8 |
|
|
7.2 |
|
Contingent consideration |
|
|
9.6 |
|
|
13.2 |
|
Long-term debt |
|
|
69.3 |
|
|
99.1 |
|
Long-term deferred taxes |
|
|
62.2 |
|
|
84.4 |
|
Total
liabilities |
|
|
270.1 |
|
|
446.6 |
|
Commitments and contingencies |
|
|
|
|
Stockholders’ equity: |
|
|
|
|
Common
stock, 69.9 and 68.4 shares outstanding at March 31, 2018
and June 30, 2017 respectively |
|
|
0.7 |
|
|
0.7 |
|
Additional paid-in capital |
|
|
889.6 |
|
|
851.4 |
|
Accumulated other comprehensive income (loss) |
|
|
1.8 |
|
|
(5.5 |
) |
Retained
earnings (deficit) |
|
|
56.2 |
|
|
(68.4 |
) |
Total
Myriad Genetics, Inc. stockholders’ equity |
|
|
948.3 |
|
|
778.2 |
|
Non-Controlling Interest |
|
|
0.1 |
|
|
(0.4 |
) |
Total
stockholders' equity |
|
|
948.4 |
|
|
777.8 |
|
Total
liabilities and stockholders’ equity |
|
$ |
1,218.5 |
|
$ |
1,224.4 |
|
|
|
|
|
|
|
Consolidated Statement of Cash Flows
(Unaudited) |
(in millions) |
|
|
|
|
|
|
|
|
|
Nine months ended |
|
|
March 31, |
|
|
2018 |
|
2017 |
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
Net Income attributable
to Myriad Genetics, Inc. stockholders |
|
$ |
124.6 |
|
|
|
8.9 |
|
Adjustments to reconcile net income to net cash provided by
operating activities: |
|
|
|
|
Depreciation and amortization |
|
|
39.3 |
|
|
|
35.0 |
|
Non-cash
interest expense |
|
|
0.1 |
|
|
|
0.4 |
|
Loss
(gain) on disposition of assets |
|
|
0.1 |
|
|
|
(0.2 |
) |
Share-based compensation expense |
|
|
20.0 |
|
|
|
22.7 |
|
Impairment of cost basis investment |
|
|
— |
|
|
|
2.4 |
|
Bad debt
expense |
|
|
23.2 |
|
|
|
27.3 |
|
Loss on
extinguishment of debt |
|
|
— |
|
|
|
1.3 |
|
Deferred
income taxes |
|
|
(24.9 |
) |
|
|
2.0 |
|
Unrecognized tax benefits |
|
|
2.7 |
|
|
|
0.9 |
|
Change in
fair value of contingent consideration |
|
|
(61.3 |
) |
|
|
2.0 |
|
Payment
of contingent consideration |
|
|
(20.8 |
) |
|
|
— |
|
Changes
in assets and liabilities: |
|
|
|
|
Prepaid
expenses |
|
|
2.7 |
|
|
|
10.9 |
|
Trade
accounts receivable |
|
|
(42.3 |
) |
|
|
(40.3 |
) |
Other
receivables |
|
|
4.1 |
|
|
|
(3.2 |
) |
Inventory |
|
|
8.9 |
|
|
|
(6.5 |
) |
Prepaid
taxes |
|
|
(3.7 |
) |
|
|
3.6 |
|
Accounts
payable |
|
|
(2.0 |
) |
|
|
2.0 |
|
Accrued
liabilities |
|
|
(2.6 |
) |
|
|
(0.6 |
) |
Deferred
revenue |
|
|
(0.1 |
) |
|
|
1.0 |
|
Net cash provided by
operating activities |
|
|
68.0 |
|
|
|
69.6 |
|
CASH FLOWS FROM
INVESTING ACTIVITIES |
|
|
|
|
Capital
expenditures |
|
|
(6.6 |
) |
|
|
(5.4 |
) |
Acquisitions, net of
cash acquired |
|
|
— |
|
|
|
(216.1 |
) |
Sale of cost basis
investment |
|
|
— |
|
|
|
2.6 |
|
Purchases of marketable
investment securities |
|
|
(79.4 |
) |
|
|
(74.6 |
) |
Proceeds from
maturities and sales of marketable investment securities |
|
|
65.5 |
|
|
|
142.9 |
|
Net cash used in
investing activities |
|
|
(20.5 |
) |
|
|
(150.6 |
) |
CASH FLOWS FROM
FINANCING ACTIVITIES: |
|
|
|
|
Net proceeds from
common stock issued under share-based compensation plans |
|
|
18.2 |
|
|
|
1.3 |
|
Net proceeds from
revolving credit facility |
|
|
53.0 |
|
|
|
204.0 |
|
Repayment of revolving
credit facility |
|
|
(83.0 |
) |
|
|
(37.0 |
) |
Net proceeds from term
loan |
|
|
— |
|
|
|
199.0 |
|
Repayment of term
loan |
|
|
— |
|
|
|
(200.0 |
) |
Payment of contingent
consideration recorded in purchase accounting |
|
|
(42.4 |
) |
|
|
— |
|
Fees paid for
extinguishment of debt |
|
|
— |
|
|
|
(0.6 |
) |
Repurchase and
retirement of common stock |
|
|
— |
|
|
|
(31.6 |
) |
Proceeds from
non-controlling interest |
|
|
0.5 |
|
|
|
— |
|
Net cash provided by
(used in) financing activities |
|
|
(53.7 |
) |
|
|
135.1 |
|
Effect of foreign
exchange rates on cash and cash equivalents |
|
|
1.2 |
|
|
|
1.2 |
|
Net increase (decrease)
in cash and cash equivalents |
|
|
(5.0 |
) |
|
|
55.3 |
|
Cash and cash
equivalents at beginning of the period |
|
|
102.4 |
|
|
|
68.5 |
|
Cash and
cash equivalents at end of the period |
|
$ |
97.4 |
|
|
$ |
123.8 |
|
|
|
|
|
|
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to the Company’s belief that its strategy to
build upon the solid foundation of its hereditary cancer business
with new product growth will deliver future revenue and earnings
growth; anticipated publication around the end of fiscal year 2018
of the manuscript reporting results of the randomized controlled
trial study of GeneSight Psychotropic testing; the Company’s plans
to move the Vectra DA customer service group and commercial
laboratory to its Salt Lake City headquarters and complete both
moves by the end of fiscal year 2019; the Company’s restructuring
plan to shift all laboratory-developed testing to United States
laboratories, including the sale of the Clinic; the Company’s
increased fiscal full year revenue guidance of total revenue of
$771 to $773 million, GAAP diluted earnings per share guidance of
$1.87 to $1.89, and adjusted earnings per share guidance of $1.19
to $1.21, as further discussed under the captions “Fiscal Year 2018
Financial Guidance” and “Reconciliation of GAAP to Non-GAAP for
Fiscal Year 2018”; and the Company’s strategic directives under the
caption “About Myriad Genetics.” These “forward-looking statements”
are based on management’s current expectations of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those
described or implied in the forward-looking statements. These risks
include, but are not limited to: the risk that sales and profit
margins of the Company’s existing molecular diagnostic tests and
pharmaceutical and clinical services may decline or will not
continue to increase at historical rates; risks related to the
Company’s ability to transition from its existing product portfolio
to the Company’s new tests; risks related to changes in the
governmental or private insurers’ reimbursement levels for the
Company’s tests or the Company’s ability to obtain reimbursement
for its new tests at comparable levels to its existing tests; risks
related to increased competition and the development of new
competing tests and services; the risk that the Company may be
unable to develop or achieve commercial success for additional
molecular diagnostic tests and pharmaceutical and clinical services
in a timely manner, or at all; the risk that the Company may not
successfully develop new markets for its molecular diagnostic tests
and pharmaceutical and clinical services, including the Company’s
ability to successfully generate revenue outside the United States;
the risk that licenses to the technology underlying the Company’s
molecular diagnostic tests and pharmaceutical and clinical services
tests and any future tests are terminated or cannot be maintained
on satisfactory terms; risks related to delays or other problems
with operating the Company’s laboratory testing facilities; risks
related to public concern over the Company’s genetic testing in
general or the Company’s tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to the
Company’s ability to obtain new corporate collaborations or
licenses and acquire new technologies or businesses on satisfactory
terms, if at all; risks related to the Company’s ability to
successfully integrate and derive benefits from any technologies or
businesses that it licenses or acquires, including but not limited
to the Company’s acquisition of Assurex, Sividon and the Clinic;
risks related to the Company’s projections about the potential
market opportunity for the Company’s products; the risk that the
Company or its licensors may be unable to protect or that third
parties will infringe the proprietary technologies underlying the
Company’s tests; the risk of patent-infringement claims or
challenges to the validity of the Company’s patents; risks related
to changes in intellectual property laws covering the Company’s
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; the risk that
the Company may be unable to comply with financial operating
covenants under the Company’s credit or lending agreements; the
risk that the Company will be unable to pay, when due, amounts due
under the Company’s credit or lending agreements; and other factors
discussed under the heading “Risk Factors” contained in Item 1A of
the Company’s most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in the Company’s Quarterly
Reports on Form 10-Q or Current Reports on Form 8-K.
Statement regarding use of non-GAAP financial
measuresIn this press release, the Company’s financial
results and financial guidance are provided in accordance with
accounting principles generally accepted in the United States
(GAAP) and using certain non-GAAP financial measures. Management
believes that presentation of operating results using non-GAAP
financial measures provides useful supplemental information to
investors and facilitates the analysis of the Company’s core
operating results and comparison of operating results across
reporting periods. Management also uses non-GAAP financial measures
to establish budgets and to manage the Company’s business. A
reconciliation of the GAAP financial results to non-GAAP financial
results is included in the attached schedules.
Following is a description of the adjustments made to GAAP
financial measures:
- Acquisition – amortization of intangible assets: Represents
recurring amortization charges resulting from the acquisition of
intangible assets, including developed technology and database
rights.
- Acquisition – integration related costs: Costs related to
closing and integration of acquired companies
- Tax impact related to equity compensation: Changes in effective
tax rate based upon ASU 2016-09
- Potential future consideration related to acquisitions:
Non-cash expenses related to valuation adjustments of earn-out and
milestone payments tied to recent acquisitions
- Impairment of Raindance Investment: One-time impairment charge
associated with Myriad’s investment in Raindance Technologies
- One-time debt restructuring costs: Charges related to the
restructuring of the company’s debt from a one-year term loan to a
revolving credit facility
- One-time non-deductible costs: One-time non-deductible tax
items
- Tax reform impact on deferred taxes: One-time non-cash charges
associated with change in value of our deferred tax assets due to
tax reform
- Elevate 2020 costs: Expenses tied to Elevate 2020 program
The Company encourages investors to carefully consider its
results under GAAP, as well as its supplemental non-GAAP
information and the reconciliation between these presentations, to
more fully understand its business. Non-GAAP financial results are
reported in addition to, and not as a substitute for, or superior
to, financial measures calculated in accordance with
GAAP.
|
|
|
|
|
|
|
|
Reconciliation
of GAAP to Non-GAAP Financial
Measures |
|
|
|
|
|
|
|
for the Three
and Nine Months ended March 31, 2018 |
|
|
|
|
|
|
|
(Unaudited data in
millions, except per share amount) |
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
Mar 31, 2018 |
|
Mar 31, 2017 |
|
Mar 31, 2018 |
|
Mar 31, 2017 |
|
|
|
|
|
|
|
|
Revenue |
$ |
193.5 |
|
|
$ |
196.9 |
|
|
$ |
577.7 |
|
|
$ |
570.9 |
|
|
|
|
|
|
|
|
|
GAAP Cost of
molecular diagnostic testing |
$ |
36.8 |
|
|
$ |
37.9 |
|
|
$ |
110.7 |
|
|
$ |
109.5 |
|
GAAP Cost of
pharmaceutical and clinical
services |
|
7.3 |
|
|
|
6.4 |
|
|
|
20.7 |
|
|
|
19.1 |
|
Elevate
2020 costs |
|
(0.2 |
) |
|
|
- |
|
|
|
(0.2 |
) |
|
|
- |
|
Non-GAAP
COGS |
$ |
43.9 |
|
|
$ |
44.3 |
|
|
$ |
131.2 |
|
|
$ |
128.6 |
|
|
|
|
|
|
|
|
|
Non-GAAP Gross
Margin |
|
77 |
% |
|
|
78 |
% |
|
|
77 |
% |
|
|
77 |
% |
|
|
|
|
|
|
|
|
GAAP Research
and Development |
$ |
18.5 |
|
|
$ |
17.6 |
|
|
$ |
53.1 |
|
|
$ |
55.6 |
|
Acquisition - Integration related costs |
|
(0.1 |
) |
|
|
(0.1 |
) |
|
|
(0.1 |
) |
|
|
(0.2 |
) |
Acquisition - amortization of intangible assets |
|
- |
|
|
|
- |
|
|
|
(0.3 |
) |
|
|
(0.2 |
) |
Elevate
2020 costs |
|
(1.0 |
) |
|
|
- |
|
|
|
(1.1 |
) |
|
|
- |
|
Non-GAAP
R&D |
$ |
17.4 |
|
|
$ |
17.5 |
|
|
$ |
51.6 |
|
|
$ |
55.2 |
|
|
|
|
|
|
|
|
|
GAAP Contingent
Consideration |
$ |
(1.2 |
) |
|
$ |
5.2 |
|
|
$ |
(61.3 |
) |
|
$ |
2.0 |
|
Potential
future consideration related to acquisitions |
|
1.2 |
|
|
|
(5.2 |
) |
|
|
61.3 |
|
|
|
(2.0 |
) |
Non-GAAP
Contingent Consideration |
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
|
|
|
|
|
|
|
GAAP Selling,
General and Administrative |
$ |
115.1 |
|
|
$ |
122.1 |
|
|
$ |
345.5 |
|
|
$ |
354.3 |
|
Acquisition - Integration related costs |
|
(0.3 |
) |
|
|
(1.8 |
) |
|
|
(0.3 |
) |
|
|
(12.8 |
) |
Acquisition - amortization of intangible assets |
|
(9.2 |
) |
|
|
(9.2 |
) |
|
|
(27.5 |
) |
|
|
(23.6 |
) |
Elevate
2020 costs |
|
(2.0 |
) |
|
|
- |
|
|
|
(4.7 |
) |
|
|
- |
|
Non-GAAP
SG&A |
$ |
103.6 |
|
|
$ |
111.1 |
|
|
$ |
313.0 |
|
|
$ |
317.9 |
|
|
|
|
|
|
|
|
|
GAAP Operating
Income |
$ |
17.0 |
|
|
$ |
7.7 |
|
|
$ |
109.0 |
|
|
$ |
30.4 |
|
Acquisition - Integration related costs |
|
0.4 |
|
|
|
1.9 |
|
|
|
0.4 |
|
|
|
13.0 |
|
Acquisition - amortization of intangible assets |
|
9.2 |
|
# |
|
9.2 |
|
|
|
27.8 |
|
|
|
23.8 |
|
Elevate
2020 costs |
|
3.2 |
|
|
|
- |
|
|
|
6.0 |
|
|
|
- |
|
Potential
future consideration related to acquisitions |
|
(1.2 |
) |
|
|
5.2 |
|
|
|
(61.3 |
) |
|
|
2.0 |
|
Non-GAAP
Operating Income |
$ |
28.6 |
|
|
$ |
24.0 |
|
|
$ |
81.9 |
|
|
$ |
69.2 |
|
|
|
|
|
|
|
|
|
Non-GAAP
Operating Margin |
|
15 |
% |
|
|
12 |
% |
|
|
14 |
% |
|
|
12 |
% |
|
|
|
|
|
|
|
|
GAAP Net Income
Attributable to Myriad Genetics, Inc. Stockholders |
$ |
11.4 |
|
|
|
4.2 |
|
|
$ |
124.6 |
|
|
$ |
9.0 |
|
Acquisition - Integration related costs |
|
0.4 |
|
|
|
1.9 |
|
|
|
0.4 |
|
|
|
13.0 |
|
Acquisition - amortization of intangible assets |
|
9.2 |
|
|
|
9.2 |
|
|
|
27.8 |
|
|
|
23.8 |
|
Elevate
2020 costs |
|
3.2 |
|
|
|
- |
|
|
|
6.0 |
|
|
|
- |
|
Potential
future consideration related to acquisitions |
|
(1.2 |
) |
|
|
5.2 |
|
|
|
(61.3 |
) |
|
|
2.0 |
|
Tax
impact related to equity compensation |
|
0.1 |
|
|
|
(0.1 |
) |
|
|
(0.3 |
) |
|
|
2.9 |
|
One-time
debt restructuring costs |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1.3 |
|
One-time
non-deductible costs |
|
- |
|
|
|
(1.5 |
) |
|
|
- |
|
|
|
2.7 |
|
Tax
reform effect on deferred taxes |
|
- |
|
|
|
- |
|
|
|
(32.6 |
) |
|
|
- |
|
Impairment of Raindance Investment |
|
- |
|
|
|
(0.1 |
) |
|
|
- |
|
|
|
3.3 |
|
Tax
effect associated with non-GAAP adjustments |
|
(0.8 |
) |
|
|
(0.7 |
) |
|
|
(1.8 |
) |
|
|
(6.3 |
) |
Non-GAAP Net
Income |
$ |
22.3 |
|
|
$ |
18.1 |
|
|
$ |
62.8 |
|
|
$ |
51.7 |
|
|
|
|
|
|
|
|
|
GAAP Diluted
EPS |
$ |
0.16 |
|
|
$ |
0.06 |
|
|
$ |
1.74 |
|
|
$ |
0.13 |
|
Non-GAAP
Diluted EPS |
$ |
0.31 |
|
|
$ |
0.27 |
|
|
$ |
0.88 |
|
|
$ |
0.75 |
|
|
|
|
|
|
|
|
|
Diluted shares
outstanding |
|
72.4 |
|
|
|
68.3 |
|
|
|
71.7 |
|
|
|
68.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Cash Flow
Reconciliation |
|
|
|
|
|
|
|
(Unaudited data in
millions) |
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
Mar 31, 2018 |
|
Mar 31, 2017 |
|
Mar 31, 2018 |
|
Mar 31, 2017 |
|
|
|
|
|
|
|
|
GAAP cash flow
from operations |
$ |
11.5 |
|
|
$ |
41.1 |
|
|
$ |
68.0 |
|
|
$ |
69.6 |
|
Capital
expenditures |
|
(2.9 |
) |
|
|
(1.5 |
) |
|
|
(6.6 |
) |
|
|
(5.4 |
) |
Free cash
flow |
$ |
8.6 |
|
|
$ |
39.6 |
|
|
$ |
61.4 |
|
|
$ |
64.2 |
|
|
|
|
|
|
|
|
|
Elevate 2020 costs |
|
3.2 |
|
|
|
- |
|
|
|
6.0 |
|
|
|
- |
|
Acquisition -
Integration related costs |
|
0.4 |
|
|
|
1.9 |
|
|
|
0.4 |
|
|
|
9.8 |
|
Cash paid for
contingent consideration in operating cash flows |
|
20.8 |
|
|
|
- |
|
|
|
20.8 |
|
|
|
- |
|
Cash paid at closing to
Assurex vendors |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
6.8 |
|
Tax effect associated
with non-GAAP adjustments |
|
(0.8 |
) |
|
|
(0.7 |
) |
|
|
(1.8 |
) |
|
|
(6.4 |
) |
Non-GAAP Free
cash flow |
$ |
32.2 |
|
|
$ |
40.8 |
|
|
$ |
86.8 |
|
|
$ |
74.4 |
|
|
|
|
|
|
|
|
|
Reconciliation of GAAP to Non-GAAP for Fiscal Year
2018 The Company’s future performance and financial
results are subject to risks and uncertainties, and actual results
could differ materially from guidance set forth below. Some of the
factors that could affect the Company’s financial results are
stated in the safe harbor statement of this press release. More
information on potential factors that could affect the Company’s
financial results are included under the heading "Risk Factors"
contained in Item 1A in the Company’s most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, as
well as any updates to those risk factors filed from time to time
in the Company’s Quarterly Reports on Form 10-Q or Current Reports
on Form 8-K.
|
|
Fiscal Year 2018 |
Diluted net income per share |
|
GAAP
diluted net income per share |
$1.87 - $1.89 |
|
Acquisition
- amortization of intangible assets |
0.52 |
|
Change in
contingent consideration |
(0.85 |
) |
Tax reform
impact on deferred taxes |
(0.44 |
) |
One-time expenses |
|
0.09 |
|
Non-GAAP diluted net income per share |
$1.19 - $1.21 |
|
|
|
|
Media Contact:
Ron Rogers(801) 584-3065rrogers@myriad.com
Investor Contact:
Scott Gleason(801) 584-1143sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024